Atopic Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Atopic Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112025A6659

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Atopic Dermatitis  - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence

5 Atopic Dermatitis  - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Atopic Dermatitis  - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (​2024-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (​2024-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (​2024-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (​2024-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (​2024-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (​2024-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (​2024-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (​2024-2034​)

8 Atopic dermatitis  - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Atopic Dermatitis  - Unmet Needs

10 Atopic Dermatitis  - Key Endpoints of Treatment

11 Atopic Dermatitis  - Marketed Products
11.1 List of Atopic dermatitis Marketed Drugs Across the Top 7 Markets
11.1.1    Ruxolitinib - Novartis

11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2    Upadacitinib - AbbVie
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3    Difamilast - Otsuka Pharmaceutical
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4    Abrocitinib - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5    Dupilumab - Regeneron Pharmaceuticals
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.

12 Atopic Dermatitis  - Pipeline Drugs
12.1 List of Atopic dermatitis  Pipeline Drugs Across the Top 7 Markets
12.1.1 Ivarmacitinib - Reistone Biopharma

12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ustekinumab - Janssen Pharmaceutical
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 si 544 - selectION
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Benralizumab - AstraZeneca
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Lebrikizumab - Eli Lilly and Company 
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

13. Atopic Dermatitis  - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Atopic Dermatitis  - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets

14.2.1    Atopic Dermatitis  - Market Size
14.2.1.1 Market Size (​2018-2023​)
14.2.1.2 Market Forecast (​2024-2034​)
14.2.2    Atopic Dermatitis  - Market Size by Therapies
14.2.2.1 Market Size by Therapies (​2018-2023​)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1    Atopic Dermatitis  - Market Size
14.3.1.1 Market Size (​2018-2023​)
14.3.1.2 Market Forecast (​2024-2034​)
14.3.2    Atopic Dermatitis  - Market Size by Therapies
14.3.2.1 Market Size by Therapies (​2018-2023​)
14.3.2.2 Market Forecast by Therapies (​2024-2034​)
14.3.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Atopic Dermatitis  - Market Size
14.4.1.1 Market Size (​2018-2023​)
14.4.1.2 Market Forecast (​2024-2034​)
14.4.2    Atopic Dermatitis  - Market Size by Therapies
14.4.2.1 Market Size by Therapies (​2018-2023​)
14.4.2.2 Market Forecast by Therapies (​2024-2034​)
14.4.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Atopic Dermatitis  - Market Size
14.5.1.1 Market Size (​2018-2023​)
14.5.1.2 Market Forecast (​2024-2034​)
14.5.2    Atopic Dermatitis  - Market Size by Therapies
14.5.2.1 Market Size by Therapies (​2018-2023​)
14.5.2.2 Market Forecast by Therapies (​2024-2034​)
14.5.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Atopic Dermatitis  - Market Size
14.6.1.1 Market Size (​2018-2023​)
14.6.1.2 Market Forecast (​2024-2034​)
14.6.2    Atopic Dermatitis  - Market Size by Therapies
14.6.2.1 Market Size by Therapies (​2018-2023​)
14.6.2.2 Market Forecast by Therapies (​2024-2034​)
14.6.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Atopic Dermatitis  - Market Size
14.7.1.1 Market Size (​2018-2023​)
14.7.1.2 Market Forecast (​2024-2034​)
14.7.2    Atopic Dermatitis  - Market Size by Therapies
14.7.2.1 Market Size by Therapies (​2018-2023​)
14.7.2.2 Market Forecast by Therapies (​2024-2034​)
14.7.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Atopic Dermatitis  - Market Size
14.8.1.1 Market Size (​2018-2023​)
14.8.1.2 Market Forecast (​2024-2034​)
14.8.2    Atopic Dermatitis  - Market Size by Therapies
14.8.2.1 Market Size by Therapies (​2018-2023​)
14.8.2.2 Market Forecast by Therapies (​2024-2034​)
14.8.3    Atopic Dermatitis  - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Atopic Dermatitis   - Market Size
14.9.1.1 Market Size (​2018-2023​)
14.9.1.2 Market Forecast (​2024-2034​)
14.9.2    Atopic Dermatitis  - Market Size by Therapies
14.9.2.1 Market Size by Therapies (​2018-2023​)
14.9.2.2 Market Forecast by Therapies (​2024-2034​)
14.9.3    Atopic Dermatitis  - Access and Reimbursement Overview

15 Atopic Dermatitis  - Recent Events and Inputs From Key Opinion Leaders

16 Atopic Dermatitis Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
 
17 Appendix

Atopic Dermatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials